Related Experiment Videos
Hyperhemolytic transfusion reaction in sickle cell disease.
1Red Cell Immunohaematology, National Blood Service-South Thames Centre, London, UK. nay.win@nbs.nhs.uk
Transfusion
|March 29, 2001
Summary
Severe hemolytic transfusion reactions (HTR) in sickle cell disease (SCD) involve destruction of sickle cells and reticulocytes by macrophages. Intravenous immunoglobulin (IVIG) and steroids may halt hemolysis by blocking adhesion and suppressing macrophage activity.
Area of Science:
- Hematology
- Immunology
- Transfusion Medicine
Background:
- Atypical hemolytic transfusion reactions (HTR) are life-threatening in sickle cell disease (SCD).
- The exact pathophysiologic mechanism of HTR in SCD remains poorly understood.
- Continuing blood transfusions can worsen hemolysis in these patients.
Observation:
- Two cases of severe HTR after compatible RBC transfusion in SCD patients were analyzed.
- Hemolysis of both autologous and transfused cells was confirmed via urine Hb HPLC.
- Multispecific HLA antibodies were detected, and reticulocytopenia was observed during the acute phase.
Findings:
- Sickle cells and sickle reticulocytes exhibit increased adherence to macrophages in SCD.
- Reticulocytopenia during HTR is likely due to peripheral consumption by macrophages, not suppressed erythropoiesis.
- Bone marrow examination revealed erythroid hyperplasia during reticulocytopenia.
Implications:
- IVIG and steroid therapy may resolve hemolysis by inhibiting sickle cell-macrophage adhesion.
- Steroids may suppress macrophage activity, contributing to the cessation of hemolysis.
- Understanding these mechanisms can guide management of HTR in SCD patients.